Article Text
Editorial commentary
Maximising returns: combining newborn screening with gene therapy for spinal muscular atrophy
Statistics from Altmetric.com
Footnotes
Contributors The author solely contributed to this article.
Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests The author has served on spinal muscular atrophy advisory boards for Roche.
Provenance and peer review Commissioned; internally peer reviewed.